+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 100Years
All Genders
ID07700238

Evaluating Romiplostim Plus Prednisolone Versus Prednisolone Alone for Adults With Untreated Primary Immune Thrombocytopenia A Phase 3 Randomized Study

Led by Amgen · Updated on 2026-09-17

126

Participants Needed

3

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating how well romiplostim combined with prednisolone works and how safe it is compared to prednisolone alone in adults with Primary Immune Thrombocytopenia ITP who have not been treated before. This Phase 3 study focuses on adults diagnosed with primary ITP that requires treatment, aiming to improve platelet response and reduce bleeding risks. Participants are randomly assigned to one of two groups. One group receives romiplostim by injection under the skin combined with oral prednisolone, while the other group receives only oral prednisolone. These treatments are given during the first part of the study, and those who finish this part continue into a second part for further assessments. Throughout the study, participants undergo various evaluations including platelet counts, bleeding assessments, and questionnaires about symptoms and quality of life, conducted over several months. Researchers also monitor safety by tracking adverse events and antibody development. The main outcome is the percentage of participants with a lasting platelet response measured over 8 weeks, with follow-up assessments extending up to 12 months to evaluate longer-term effects and safety.

CONDITIONS

Brief Title

A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP)

Research Team

A

Amgen Call Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here